Climb Bio, Inc. Files 8-K with Corporate Updates

Ticker: CLYM · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1768446

Climb Bio, INC. 8-K Filing Summary
FieldDetail
CompanyClimb Bio, INC. (CLYM)
Form Type8-K
Filed DateOct 2, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, filing, pharmaceutical

TL;DR

Climb Bio (formerly Eliem) filed an 8-K on Oct 2, 2024, updating corporate docs & financials.

AI Summary

Climb Bio, Inc. filed an 8-K on October 2, 2024, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements. The company, formerly known as Eliem Therapeutics, Inc. until February 19, 2019, is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides an update on Climb Bio, Inc.'s corporate structure and financial reporting, which is important for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

FAQ

What specific amendments were made to Climb Bio, Inc.'s articles of incorporation or bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the excerpt.

What are the 'Other Events' reported in this 8-K filing?

The excerpt does not specify the nature of the 'Other Events' reported by Climb Bio, Inc.

When did Climb Bio, Inc. change its name from Eliem Therapeutics, Inc.?

The company changed its name from Eliem Therapeutics, Inc. on February 19, 2019.

What is Climb Bio, Inc.'s Standard Industrial Classification (SIC) code?

Climb Bio, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the principal executive office address for Climb Bio, Inc.?

The principal executive office address is PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE 19808-1609.

Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2024-10-02 16:15:00

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation 3.2 Amended and Restated Bylaws 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: October 2, 2024 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing